Interest by the pharmaceutical industry to register medicines through Malta has increased, according to the Chairperson of the Malta Medicines Authority, Professor Anthony Serracino Inglott.
During a meeting earlier this month to engage with stakeholders on the approach to potential Brexit scenarios, Prof. Serracino Inglott said that the Authority is optimising its role within the European regulatory network and maintaining its strong working relationships with UK colleagues. He assured the full commitment of its highly qualified professionals to support the registration of medicines in Malta.
Parliamentary Secretary for Consumer Protection and Valletta 2018, Dr Deo Debattista, who addressed the stakeholder meeting at the Malta Life Sciences Park, emphasised how the Government is committed to ensure availability of medicines post-Brexit which satisfy the rigorous EU quality assurance requirements.
He assured those involved in pharmaceuticals that the Government is pro-business which is of benefit to the country and supports the private sector in its endeavour to ensure continuous supply of medicines following Brexit. The possibility of positive opportunities emerging from Brexit related to healthcare, such as the establishment in Malta of offices for notified bodies for medical devices was also explored.
Together with other Member States and the European Medicines Agency, the Malta Medicines Authority has taken a proactive approach to support stakeholders in their business continuity for the benefit of patients. The Authority is undergoing capacity building to deal with the increased demands for its services and is providing targeted advice and training. All stakeholders requiring clarification or assistance from the Medicines Authority, especially related to the registration of medicines, may contact the Director for Licensing, Helen Vella.